3,4-双[(4-甲氧基苯基)甲氧基]苯甲醛 | 88015-48-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,4-双[(4-甲氧基苯基)甲氧基]苯甲醛
• 英文名称: 3,4-bis((4-methoxybenzyl)oxy)benzaldehyde
• 英文别名: 3,4-bis(4-methoxybenzyloxy)benzaldehyde；3,4-di(p-methoxybenzyloxy)benzaldehyde；Benzaldehyde, 3,4-bis[(4-methoxyphenyl)methoxy]-；3,4-bis[(4-methoxyphenyl)methoxy]benzaldehyde
• CAS: 88015-48-9
• 化学式: C₂₃H₂₂O₅
• 分子量: 378.425
• InChiKey: FHKJZFASBMEEOR-UHFFFAOYSA-N

物化性质

• 沸点：
  554.8±45.0 °C(Predicted)
• 密度：
  1.188±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3,4-双[(4-甲氧基苯基)甲氧基]苯甲醛 在 盐酸羟胺 、 三乙胺 作用下， 以94%的产率得到N-[[3,4-bis[(4-methoxyphenyl)methoxy]phenyl]methylidene]hydroxylamine
  参考文献：
  名称：

  Studies on New Catechol Containing Cephalosponns. I. Synthesis and Structure-activity Relationships of Cephalosponns Having a Catechol Moiety at the C-3 Position.

  摘要：

  DOI：

  10.7164/antibiotics.48.1371
• 作为产物：
  描述：

  4-甲氧基氯苄 、 3,4-二羟基苯甲醛 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以100 %的产率得到3,4-双[(4-甲氧基苯基)甲氧基]苯甲醛
  参考文献：
  名称：

  플라보노이드 유도체를 유효성분으로 포함하는 아토피 예방, 개선 또는 치료용 약학적 조성물 및 플라보노이드 유도체의 제조방법

  摘要：

  本发明涉及由黄酮类衍生物作为活性成分的预防、改善或治疗过敏症的药物组合物和黄酮类衍生物的制备方法，特别是黄酮类衍生物3'、4'-二羟基黄酮醇（3',4'-Dihydroxy flavonol）作为活性成分，用于预防、改善或治疗过敏症的药物组合物，以及制备所述3',4'-二羟基黄酮醇的方法。

  公开号：

  KR102599580B1

文献信息

• NOVEL CEPHALOSPORIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF
  申请人：CHO Young Lag

  公开号：US20120264727A1

  公开（公告）日：2012-10-18

  The present invention relates to novel cephalosporin derivatives represented by Chemical Formula 1. Wherein, X, Y, L, R 1 , and R 2 are as same as defined in the description of the invention. The present invention also relates to pharmaceutical antibiotic compositions comprising a novel celphalosporin derivative represented by Chemical Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient. According to the present invention, novel cephalosporin derivatives, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient for the broad spectrum of antibiotic resistant, low toxicity, particularly in Gram-negative bacteria, which can be useful with strong antimicrobial activity.

  本发明涉及由化学公式1表示的新型头孢菌素衍生物。其中，X、Y、L、R1和R2与发明描述中定义的相同。本发明还涉及包含由化学公式1表示的新型头孢菌素衍生物、前药、水合物、溶剂化物、异构体或药用可接受盐作为有效成分的药物抗生素组合物。根据本发明，新型头孢菌素衍生物、前药、水合物、溶剂化物、异构体或药用可接受盐作为广谱抗生素耐药、低毒性的有效成分，特别是在革兰氏阴性细菌中，可以具有强大的抗菌活性。
• Total Syntheses of Isowondonins Based on a Biosynthetic Pathway
  作者：Shuai Yu、Feng Li、Hongjun Jeon、Seokwoo Lee、Jongheon Shin、Sanghee Kim

  DOI：10.1021/acs.orglett.6b01336

  日期：2016.6.17

  The first total syntheses of (−)-isowondonin A and (−)-isowondonin B, which are unusual imidazole marine alkaloids, has been accomplished through the development of methods for the selective formation of styryl sulfate group and regioselective alkylation of the imidazole. Application of the Noyori asymmetric hydrogenation of ketones allows the asymmetric synthesis. These results in conjunction with

  通过开发选择性形成苯乙烯基硫酸酯基团和对咪唑进行区域选择性烷基化的方法，已经完成了作为非常规咪唑海洋生物碱的（-）-异黄体酮A和（-）-异黄体酮B的第一个总合成。Noyori酮不对称氢化的应用允许不对称合成。这些结果与ECD计算相结合，从而确定了异黄酮素的绝对构型。
• Phenacylpyridiniothiocephalosporins
  申请人：Shionogi & Co., Ltd.

  公开号：US05134138A1

  公开（公告）日：1992-07-28

  An antibacterial 3-vic-dihydroxyaroylmethylpyridiniothiomethyl cephalosporin (I) and its salts represented by the following formula: ##STR1## (wherein, R.sup.1 is amino group or acylamino; R.sup.2 is hydrogen or methoxy; R.sup.3 is hydrogen atom or substituent; R.sup.4 is vic-dihydroxyaryl; R.sup.5 is straight or branched lower alkylene; R.sup.6 is hydrogen, a carboxy-protecting group or combined with Y a negative charge; X is --O--, --S-- or sulfinyl; and Y is a counter-ion of pyridinio or combined with R.sup.6 a negative charge), a disinfecting and treating method of bacterial infection using it, and synthetic methods thereof are provided.

  提供一种抗菌的3-邻二羟基芳基甲基吡啶硫甲基头孢菌素(I)及其盐，其化学式如下：##STR1## (其中，R1为氨基或酰胺基；R2为氢或甲氧基；R3为氢原子或取代基；R4为邻二羟基芳基；R5为直链或分支低碳链基；R6为氢、羧基保护基或与Y结合形成负电荷；X为--O--、--S--或亚砜基；Y为吡啶硫甲基阳离子的对离子或与R6结合形成负电荷)，以及使用它进行细菌感染的消毒和治疗方法，以及其合成方法。
• NOVEL CEPHALOSPORIN DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF
  申请人：LegoChem Biosciences, Inc.

  公开号：EP2706062B1

  公开（公告）日：2018-05-09
• Imidazole-based alkaloid derivative LCB54-0009 suppresses ocular angiogenesis and lymphangiogenesis in models of experimental retinopathy and corneal neovascularization
  作者：Byung-Hak Kim、Junyeop Lee、Jun-Sub Choi、Dae Young Park、Ho Young Song、Tae Kyo Park、Chung-Hyun Cho、Sang-Kyu Ye、Choun-Ki Joo、Gou Young Koh、Tae-Yoon Kim

  DOI：10.1111/bph.13177

  日期：2015.8

  Background and PurposeAbnormally induced angiogenesis and lymphangiogenesis are associated with human diseases, including neovascular eye disease. Substances that inhibit these processes may have potential as an attractive therapeutic strategy for these diseases.Experimental ApproachIn vitro and in vivo angiogenesis and/or lymphangiogenesis were assessed in VEGF‐ or hypoxia‐stimulated endothelial and retinal cells and in animal models of oxygen‐induced retinopathy (OIR), streptozotocin‐induced diabetic retinopathy (SIDR), suture‐induced inflammatory corneal neovascularization (SICNV) and silver nitrate‐induced corneal neovascularization. HUVECs and retinal cells were cultured under hypoxic conditions or incubated with VEGF to identify the molecular mechanisms involved.Key ResultsThe imidazole‐based alkaloid derivative LCB54‐0009 inhibited capillary‐like tube formation in VEGF‐induced HUVECs without inducing cytotoxic effects. Intravitreal injection of LCB54‐0009 into retinas suppressed the formation of the pathological neovascular tufts and increased vascular permeability in both OIR of mice and SIDR of rats. Furthermore, subconjunctival injection of LCB54‐0009 into the cornea suppressed corneal inflammation and inflammation‐associated angiogenesis and lymphangiogenesis in SICNV of mice and silver nitrate cauterization of rats. These pharmacological activities were associated with effects on HIF‐1α protein stability and HIF‐1α/NF‐κB redox sensitivity through its antioxidant activities. LCB54‐0009 also inhibited the hypoxia‐induced expression of angiopoietin‐2, and VEGF‐induced VEGFR‐2 activation and downstream signalling, resulting in the down‐regulation of the expression of pro‐angiogenic factors and pro‐inflammatory mediators and an up‐regulation of the expression of anti‐angiogenic factors.Conclusions and ImplicationsLCB54‐0009 is a potential candidate molecule for blocking pathological angiogenesis and lymphangiogenesis mediated by HIF‐1α‐ angiopoietin‐2 expression and VEGFR‐2 activation.